Shaheen Abdel Aziz, Riazi Kiarash, Medellin Alexandra, Bhayana Deepak, Kaplan Gilaad G, Jiang Jason, Park Roy, Schaufert Wendy, Burak Kelly W, Sargious Monica, Swain Mark G
Division of Gastroenterology and Hepatology (Shaheen, Riazi, Kaplan, Burak, Swain), Department of Medicine, University of Calgary; EFW Radiology group (Medellin, Bhayana, Park); Alberta Health Services (Jiang, Schaufert); Community Primary Care, Alberta Health Services (Sargious), Calgary, Alta.
CMAJ Open. 2020 May 15;8(2):E370-E376. doi: 10.9778/cmajo.20200009. Print 2020 Apr-Jun.
Identification of patients with nonalcoholic fatty liver disease (NAFLD) with advanced liver fibrosis in primary care remains an unmet need. Our primary objective was to implement a pathway driven by shear wave elastography (SWE) to facilitate risk stratification of patients with NAFLD within primary care and evaluate whether SWE assessment can reduce referrals of patients with NAFLD at low risk for fibrosis to hepatology.
A multidisciplinary NAFLD clinical care pathway was codeveloped by hepatologists, radiologists and primary care physicians in Calgary to provide access to SWE-based screening of patients with NAFLD risk factors in primary care. The study outcome measures were estimated NAFLD-related referrals to the hepatology service in Calgary after implementation of the NAFLD pathway and characteristics of patients with NAFLD at risk for advanced fibrosis. The NAFLD pathway was implemented in January 2018 and was made available to all primary care physicians in the Calgary Health Zone. Patients with NAFLD who had liver stiffness (SWE value ≥ 8.0 kPa) or an inconclusive assessment were referred to hepatology. A serum liver fibrosis score was also measured with the fibrosis-4 (FIB-4) index, and performance of an FIB-4 index score of 1.30 or greater to risk stratify patients with NAFLD was evaluated. Demographic, clinical and laboratory characteristics of study groups were compared.
Between March and October 2018, 2084 patients with suspected NAFLD were evaluated. Nonalcoholic fatty liver disease was confirmed by ultrasonography in 1958 (94.1%). A majority of the cohort had elevated liver enzyme values (1028 [52.5%]) and obesity (body mass index ≥ 30) (1063/1764 [60.3%]). Most patients with NAFLD (1791 [91.5%]) had an SWE value less than 8.0 kPa and were not referred to hepatology. Sixty-seven patients (3.4%) had an SWE value of 8.0 kPa or more, and 100 (5.1%) had an inconclusive SWE; these patients were referred to hepatology. Using an FIB-4 index score cut-off of 1.30 would have led to hepatology referral of 396/1251 patients (31.6%).
Implementation of a primary care-accessible SWE pathway for patients with NAFLD facilitated fibrosis risk stratification and greatly reduced hepatology referrals. Using the FIB-4 index score alone would led to higher rates of referral of patients with NAFLD.
在初级保健中识别非酒精性脂肪性肝病(NAFLD)合并晚期肝纤维化的患者仍是一项未满足的需求。我们的主要目标是实施一条由剪切波弹性成像(SWE)驱动的路径,以促进初级保健中NAFLD患者的风险分层,并评估SWE评估是否可以减少低纤维化风险的NAFLD患者转诊至肝病科。
卡尔加里的肝病学家、放射科医生和初级保健医生共同制定了一条多学科的NAFLD临床护理路径,以便在初级保健中对有NAFLD风险因素的患者进行基于SWE的筛查。研究结果指标为实施NAFLD路径后卡尔加里转诊至肝病科服务的估计NAFLD相关病例数,以及有晚期纤维化风险的NAFLD患者的特征。NAFLD路径于2018年1月实施,并提供给卡尔加里健康区的所有初级保健医生。NAFLD患者若肝脏硬度(SWE值≥8.0 kPa)或评估结果不确定,则转诊至肝病科。还使用纤维化-4(FIB-4)指数测量血清肝纤维化评分,并评估FIB-4指数评分≥1.30对NAFLD患者进行风险分层的效能。比较研究组的人口统计学、临床和实验室特征。
2018年3月至10月期间,对2084例疑似NAFLD患者进行了评估。1958例(94.1%)经超声检查确诊为非酒精性脂肪性肝病。大多数队列患者肝酶值升高(1028例[52.5%])且肥胖(体重指数≥30)(1063/1764例[60.3%])。大多数NAFLD患者(1791例[91.5%])的SWE值小于8.0 kPa,未转诊至肝病科。67例患者(3.4%)的SWE值≥8.0 kPa,100例(5.1%)的SWE评估结果不确定;这些患者转诊至肝病科。使用FIB-4指数评分临界值≥1.30会导致396/1251例患者(31.6%)转诊至肝病科。
为NAFLD患者实施可在初级保健中进行的SWE路径有助于纤维化风险分层,并大大减少了转诊至肝病科的病例数。仅使用FIB-4指数评分会导致NAFLD患者的转诊率更高。